Literature DB >> 3485182

Anterior ischaemic optic neuropathy. A correlative clinical and visual evoked potential study of 18 patients.

P D Thompson, F L Mastaglia, W M Carroll.   

Abstract

The clinical and visual evoked potential (VEP) findings were analysed in 18 patients with anterior ischaemic optic neuropathy. The VEP studies showed a variety of abnormalities which could be interpreted as being the result of subcomponent interaction consequent upon loss or attenuation of the normal macular-derived P100 component. Delay of normal VEP subcomponents was not seen. The VEP findings were non-specific but pointed to a severe disturbance of transmission in optic nerve fibres subserving central vision. No significant changes were observed with time in most cases indicating a static monophasic process with no significant recovery.

Entities:  

Mesh:

Year:  1986        PMID: 3485182      PMCID: PMC1028677          DOI: 10.1136/jnnp.49.2.128

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  19 in total

1.  Visual evoked responses in the diagnosis and management of patients suspected of multiple sclerosis.

Authors:  P Asselman; D W Chadwick; D C Marsden
Journal:  Brain       Date:  1975-06       Impact factor: 13.501

2.  Visual evoked potentials and quantitative perimetry in multiple sclerosis.

Authors:  C Ellenberger; S B Ziegler
Journal:  Ann Neurol       Date:  1977-06       Impact factor: 10.422

3.  The comparison of small-size rectangle and checkerboard stimulation for the evaluation of delayed visual evoked responses in patients suspected of multiple sclerosis.

Authors:  M Hennerici; D Wenzel; H J Freund
Journal:  Brain       Date:  1977-03       Impact factor: 13.501

4.  Acute optic neuropathy in older patients.

Authors:  C Ellenberger; J L Keltner; R M Burde
Journal:  Arch Neurol       Date:  1973-03

5.  Migraine complicated by ischaemic papillopathy.

Authors:  W I McDonald; M D Sanders
Journal:  Lancet       Date:  1971-09-04       Impact factor: 79.321

6.  Histopathology of ischemic optic neuropathy.

Authors:  P Henkind; N C Charles; J Pearson
Journal:  Am J Ophthalmol       Date:  1970-01       Impact factor: 5.258

7.  Shock-induced optic neuropathy: a cause of nonprogressive glaucoma.

Authors:  S M Drance; R W Morgan; V P Sweeney
Journal:  N Engl J Med       Date:  1973-02-22       Impact factor: 91.245

8.  Ischemic optic neuropathy: a complication of cardiopulmonary bypass surgery.

Authors:  P J Sweeney; A C Breuer; J B Selhorst; E A Waybright; A J Furlan; R J Lederman; M R Hanson; R Tomsak
Journal:  Neurology       Date:  1982-05       Impact factor: 9.910

9.  Pattern-reversal visual evoked potential. Method of analysis and results in multiple sclerosis.

Authors:  D W Collins; J L Black; F L Mastaglia
Journal:  J Neurol Sci       Date:  1978-03       Impact factor: 3.181

10.  Ischaemic optic neuropathy. The clinical profile and history.

Authors:  D R Boghen; J S Glaser
Journal:  Brain       Date:  1975-12       Impact factor: 13.501

View more
  4 in total

Review 1.  Nonarteritic anterior ischemic optic neuropathy (NAION) and its experimental models.

Authors:  Steven L Bernstein; Mary A Johnson; Neil R Miller
Journal:  Prog Retin Eye Res       Date:  2011-03-02       Impact factor: 21.198

2.  Prospective, cross-sectional study, demonstrating efficacy of blue fixation target while recording Pattern Visual Evoked Potential in optic neuropathy.

Authors:  Ajoy Vincent; Rohit Shetty; Mathew Kurian; Bhujang K Shetty
Journal:  Doc Ophthalmol       Date:  2009-06-10       Impact factor: 2.379

3.  Multifocal visual evoked potential in optic neuritis, ischemic optic neuropathy and compressive optic neuropathy.

Authors:  Manju Jayaraman; Rashmin Anilkumar Gandhi; Priya Ravi; Parveen Sen
Journal:  Indian J Ophthalmol       Date:  2014-03       Impact factor: 1.848

Review 4.  Clinical electrophysiology of the optic nerve and retinal ganglion cells.

Authors:  Oliver R Marmoy; Suresh Viswanathan
Journal:  Eye (Lond)       Date:  2021-06-11       Impact factor: 3.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.